Table 2.
Descriptive Variables Stratified by Time Since Acute COVID-19 Illness; P Value Shown Based on Chi-square or T Test Where Appropriate; Significant Values <.05; Table Based on 286 Participants as 4 Were Missing Dates of Acute Illness
| . | 26–89 (Median, 61) Days Post–Acute COVID-19 | 90–220 (Median, 139) Days Post–Acute COVID-19 | Total | P Value |
|---|---|---|---|---|
| n = 88 | n = 198 | n = 286 | ||
| Age, mean (SD), y | 46 (16) | 45 (14) | 45 (15) | .35 |
| Female sex | 67 (76.1) | 147 (74.2) | 214 (74.8) | .73 |
| Racea (279) | .26 | |||
| White | 41 (47.7) | 79 (40.9) | 120 (43) | |
| Black/African American | 33 (38.4) | 90 (46.6) | 123 (44.1) | |
| Hispanic/Latinx | 3 (3.5) | 10 (5.2) | 13 (4.7) | |
| Asian | 3 (3.5) | 9 (4.7) | 12 (4.3) | |
| Native Hawaiian/Pacific Islander | 0 | 1 (0.5) | 1 (0.4) | |
| Other | 6 (7) | 4 (2.1) | 10 (3.6) | |
| Hospitalized | 9 (10.6) | 25 (13.3) | 34 (12.4) | .54 |
| Provider-defined disease severityb | .78 | |||
| Mild | 56 (67.5) | 126 (69.2) | 182 (68.7) | |
| Moderate | 27 (32.5) | 54 (29.7) | 81 (30.6) | |
| Severe | 0 | 2 (1.1) | 2 (0.8) | |
| Persistent symptoms | ||||
| Any | 34 (38.6) | 79 (39.9) | 113 (39.5) | .84 |
| Fatigue | 17 (19.3) | 42 (21.2) | 59 (20.6) | .71 |
| Dyspnea on exertion | 16 (18.2) | 25 (12.6) | 41 (14.3) | .22 |
| Mental fog | 12 (13.6) | 27 (13.6) | 39 (13.6) | 1.0 |
| Difficulty sleeping | 10 (11.4) | 22 (11.1) | 32 (11.2) | .95 |
| Loss of smell | 12 (13.6) | 21 (10.6) | 33 (11.5) | .46 |
| Headache | 8 (9.1) | 23 (11.6) | 31 (10.8) | .53 |
| Dry cough | 8 (9.1) | 17 (8.6) | 25 (8.7) | .89 |
| Feeling depressed | 7 (8.0) | 19 (9.6) | 26 (9.1) | .66 |
| Muscle aches | 7 (8.0) | 17 (8.6) | 24 (8.4) | .86 |
| Joint pains | 6 (6.8) | 16 (8.1) | 22 (7.7) | .71 |
| Weakness | 9 (10.2) | 12 (6.1) | 21 (7.3) | .21 |
| Heart palpitations | 5 (5.7) | 16 (8.1) | 21 (7.3) | .47 |
| Anxiety/ nervousness | 4 (4.6) | 15 (7.6) | 19 (6.6) | .34 |
| Chest tightness/pain | 6 (6.8) | 13 (6.6) | 19 (6.6) | .94 |
| Loss/change in taste | 7 (8.0) | 11 (5.6) | 18 (6.3) | .44 |
| Sinus congestion | 4 (4.6) | 13 (6.6) | 17 (5.9) | .51 |
| Irritability | 5 (5.7) | 11 (5.7) | 16 (5.7) | .97 |
| Back pain | 4 (4.6) | 11 (5.6) | 15 (5.2) | .72 |
| Dizziness | 3 (3.5) | 8 (4.0) | 12 (4.2) | .84 |
| Rhinorrhea | 2 (2.3) | 9 (4.6) | 11 (3.9) | .36 |
| Ear fullness | 2 (2.3) | 8 (4.0) | 10 (3.5) | .45 |
| Heartburn | 2 (2.3) | 8 (4.0) | 10 (3.5) | .45 |
| Shortness of breath at rest | 2 (2.3) | 7 (3.5) | 9 (3.2) | .57 |
| Nausea | 1 (1.1) | 4 (2.0) | 5 (1.8) | .60 |
| Rash | 1 (1.1) | 3 (1.5) | 4 (1.4) | .80 |
| Abdominal pain | 0 (0) | 4 (2.0) | 4 (1.4) | .18 |
| Chills | 1 (1.1) | 2 (1.0) | 3 (1.1) | .92 |
| Sore throat | 1 (1.1) | 1 (0.5) | 2 (0.7) | .55 |
| Diarrhea | 0 (0) | 2 (1.0) | 2 (0.7) | .34 |
| Loss of appetite | 1 (1.1) | 0 (0) | 1 (0.4) | — |
| Other symptoms | 3 (3.4) | 11 (5.6) | 14 (4.9) | .44 |
Abbreviation: COVID-19, coronavirus disease 2019.
aAvailable for 279 participants.
bAvailable for 265 participants.